Pharmacologic inhibition with the FATP2 inhibitor lipofermata reduces tubular lipid deposition and fibrotic marker expression while restoring fatty acid oxidation programs, thereby interrupting DKD progression (13). The gene discussed is SLC27A2; the disease is diabetic kidney disease.